| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | -0.058 | 0.08 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.08 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.058 | 0.08 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.083 | 0.08 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.056 | 0.09 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.059 | 0.09 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.063 | 0.09 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.09 |